Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C43/00—Ethers; Compounds having groups, groups or groups
  • C07C43/02—Ethers
  • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
  • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
  • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
  • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
  • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C46/00—Preparation of quinones
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C46/00—Preparation of quinones
  • C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
  • C07C46/06—Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C46/00—Preparation of quinones
  • C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
  • C07C46/06—Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring
  • C07C46/08—Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring with molecular oxygen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C50/00—Quinones
  • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
  • C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure

Definitions

• This invention relates to a method for therapy of ischemic disease.
• Cerebral apoplexy and heart diseases now rank high among the causes of death, and therapeutic agents therefor are being searched for extensively.
• cytochrome C and adenosine triphosphate are known as cellular metabolism-improving agents, but cytochrome C itself sometimes causes shock symptoms in patients having an allergic constitution, while adenosine triphosphate itself sometimes causes adverse reactions such as arrhythmia.
• the present inventors have searched extensively for cellular metabolism-improving agents effective in the treatment of such ischemic diseases as cerebral circulatory disturbance, cardiac insufficiency, etc. without producing such side effects, and now have completed the present invention.
• This invention relates to:
• a method for treatment of a mammal suffering from an ischemic disease which comprises administering to said mammal an effective amount of a compound of the formula: ##STR2## wherein n is an integer of from 4 to 22, preferably from 6 to 18.
• a medicinal composition for the treatment of a mammal suffering from an ischemic disease which comprises, as an active ingredient, an effective amount of a compound of the formula [I] and a physiologically acceptable carrier, excipient or diluent therefor.
• the above-mentioned compound [I] may be exemplified by 2,3-dimethoxy-5-methyl-6-(6-hydroxyhexyl)-1,4-benzoquinone, 2,3-dimethoxy-5-methyl-6-(9-hydroxynonyl)-1,4-benzoquinone, 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone, 2,3-dimethoxy-5-methyl-6-(11-hydroxyundecyl)-1,4-benzoquinone, 2,3-dimethoxy-5-methyl-6-(12-hydroxydodecyl)-1,4-benzoquinone, 2,3-dimethoxy-5-methyl-6-(13-hydroxytridecyl)-1,4-benzoquinone, 2,3-dimethoxy-5-methyl-6-(18-hydroxyoctadecyl)-1,4-benzoquinone, 2,3-dimethoxy-5-methyl
• the compound [I] can be prepared by a per se known method, for example, the method described in U.S. Pat. No. 4,139,545 or an analogous method thereto, namely, by reacting a compound of the formula: ##STR3## with a compound of the formula:
• n has the meaning given above, to give a compound of the formula: ##STR4## wherein n has the meaning given above, and then reducing the compound [IV] by means of a reducing agent, for example, lithium aluminum hydride following oxidation with ferric chloride.
• a reducing agent for example, lithium aluminum hydride following oxidation with ferric chloride.
• the reaction of compound [II] with compound [III] is advantageously conducted in a suitable inert solvent such as, n-hexane, ligorine, toluene, xylene, acetic acid or propionic acid.
• the reaction temperature is advantageously in the range of about 80° C. to 100° C., and the reaction time is desirably in the range of about 0.5 to 3 hours.
• any procedure may be taken so long as the carboxyl may thereby be converted to an alcoholic hydroxyl.
• reduction by means of lithium aluminum hydride.
• this reduction is advantageously conducted in the presence of such a suitable solvent as diethyl ether, tetrahydrofuran and dioxane.
• the compound [I] shows an excellent cellular metabolism-improving activity in mammals (e.g. human being, mouse, rat, rabbit, dog and monkey), and it is used for alleviation or therapy of ischemic diseases especially in the brain, heart and kidneys.
• Ischemia is a localized tissue anemia due to obstruction of the inflow of artherial blood as by the narrowing of arteries by spasm or disease.
• the ischemic disease includes cerebral apoplexy (e.g.
• cardiac insufficiency cardiac infarction, angina pectoris, cardiac failure, congestive heart failure, coronary insufficiency, etc.
• renal insufficiency due to vascular changes nephrosclerosis, proteinuria due to vascular lesions, renovascular hypertension, etc.
• the compound [I] may be safely administered, orally or parenterally, as it is or advantageously as a pharmaceutical composition
• a pharmaceutical composition comprising an effective amount of the compound [I] and a physiologically acceptable carrier, excipient or diluent therefor, in the form of, for example, powder, granule, tablet, hard capsule, soft capsule, dry syrup, suppository, injection or the like.
• composition for oral administration such as powder, granule, tablet, hard capsule, soft capsule and dry syrup may be prepared by a per se known conventional manner, and may comprise carriers, excipients or diluents conventionally used in the pharmaceutical art.
• suitable carries or excipients include lactose, starch, sugar, magnesium stearate, etc.
• excipients in the preparation of soft capsules there may be used nontoxic, pharmaceutically acceptable oils and fats of animal, vegetable or mineral origin. The essential active ingredients are generally dissolved in these oils and fats before filling soft capsules therewith.
• compositions for parenteral administration may, for example, be injections and suppositories.
• the injectable preparations may be prepared in the form of solutions or suspensions. Since compounds [I] are soluble in oil but only sparingly soluble in water, injectable preparations in the form of aqueous solutions may be prepared by using solubilizing agents, if desired. As such solubilizing agents, there may be used nonionic surfactants that have adequate HLB values and are selected from among the nonionic surfactants generally used in the preparation of injectable solutions.
• the suppositories for rectal administration can be prepared by incorporating the compound [I] with a conventional suppository base.
• the composition of this invention contains a drug of dosage unit form.
• the drug of dosage unit form means a drug containing a daily dose of the compound [I] to be described hereinafter, or its multiples (up to 4 times), or its measures (down to 1/40), which is in the physically separate unit form suitable for administering as a medicine.
• Each dosage unit generally contains 0.3 mg to 100 mg of the compound [I].
• an injection ampoule preferably contains 0.3 mg to 30 mg, and each of the other forms preferably contains 5 mg to 100 mg of the compound [I].
• the dosage of the compound [I] varies with the kinds of diseases, symptoms, administration routes or dosage forms, but, in case of parenteral administration such as injection, for example, intravenous administration, the daily dose as the compound [I] is about 0.3 to 100 mg (0.006 mg to 2 mg/kg), preferably 1 mg to 30 mg (0.02 mg to 0.6 mg/kg) for adult humans, and in case of oral administration, the daily dose is about 5 mg to 600 mg (0.1 mg to 12 mg/kg), preferably 10 mg to 300 mg (0.2 mg to 6 mg/kg) for adult humans.
• the useful pharmacological activity of the compounds of the present invention has been confirmed in rats suffering from spontaneous hypertension. It is known that the strain of rats is very close to humans in such a morbid condition as cerebral apoplexy or cardiac insufficiency, that the drugs effective in humans are also effective in these rats, and that the strain therefore serves as a trustworthy model for the case of application of a drug to humans.
• Methyl 13-chloroformyltridecanoate (11.7 g) is dissolved in 200 ml of petroleum ether. To the solution is added 60 ml of ice water with ice cooling under stirring, and then 5.2 g of sodium peroxide is added to the mixture portionwise. After stirring for an hour, the reaction mixture is extracted with ether. The extract is washed with water and dried over calcium chloride, and the solvent is then distilled off under reduced pressure to give 7.6 g of crude crystals of bis-13-methoxycarbonyltridecanoyl peroxide. This product is submitted to the following step without purification.
• Lithium aluminum hydride (740 mg) is suspended in 80 ml of dried ether, and a solution of 1.06 g of 2,3-dimethoxy-6-(12-methoxycarbonyldodecyl)-5-methyl-1,4-benzoquinone in 100 ml of dried ether is added dropwise with stirring and ice cooling. After 1.5 hours, ice water is added so as to decompose the excess lithium aluminum hydride, then acidified with hydrochloric acid and extracted with ether. The extract is washed with water and concentrated under reduced pressure.
• the residue is dissolved in 30 ml of methanol, a solution of 12 g of ferric chloride in 60 ml of water is added, and the mixture is stirred at room temperature for 1.5 hours.
• the liquid reaction mixture is diluted with water and extracted with ethyl acetate.
• the extract is washed with water and dried, and the solvent is distilled off under reduced pressure.
• the residue is dissolved in chloroform and subjected to silica gel column chromatography.
• Aluminum chloride (2.5 g) is added portionwise in a nitrogen atmosphere to a solution of 1 g of methyl 21-chloroformylheneicosanoate and 1.7 g of 3,4,5-trimethoxytoluene in 50 ml of nitrobenzene, and the resulting mixture is stirred at room temperature for 48 hours.
• To the reaction mixture are added water and diluted hydrochloric acid, and the whole mixture is extracted with ether. After distilling of the solvent, the residue is dissolved in methanol, 4.6 ml of a 30% sodium hydroxide solution is added, and the mixture is stirred at 60° C. for an hour.
• the reaction mixture is washed with ether, then made acidic with diluted hydrochloric acid and extracted with ethyl acetate.
• the extract is washed with water and dried, the solvent distilled off, and the residue chromatographed on silica gel.
• the crystals recovered from the chloroform-ethanol (17:1) eluate are recrystallized from ether-hexane to give colorless crystals of 21-(2-hydroxy-3,4-dimethoxy-6-methylbenzoyl)heneicosanoic acid. m.p. 103°-150° C.
• dimethylformamide 200 ml
• 6-(22-hydroxydocosyl)-2,3-dimethoxy-5-methyl phenol 300 mg
• bis(4-hydroxysalicylidene)ethylenediiminocobalt(II) 50 mg
• the suspension is stirred in an oxygen gas stream at ambient temperature and atmospheric pressure for 7 days.
• the insoluble matter is filtered off and the filtrate is concentrated under reduced pressure.
• the residue is diluted with water and extracted with ethyl acetate.
• the extract is treated in a conventional manner and the product is chromatographed on a silica gel column.
• the dichloromethane layer is washed with water and dried over anhydrous magnesium sulfate, and the solvent is distilled off to give a light-yellow oil of 6-(11-acetoxy-1-oxoundecyl)-2,3-dimethoxy-5-methylphenol (33 g).
• This product is recrystallized from hexane to give orange-yellow needles of 6-(12-acetoxydodecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (4.8 g). m.p. 47° C.
• the dichloromethane layer is washed with water and the solvent is distilled off to give an oil (12.1 g).
• the oil is dissolved in methanol (150 ml) followed by addition of sodium hydroxide (5.2 g) and stirring at room temperature for 2 hours.
• the reaction mixture is neutralized with 5 N hydrochloric acid and the solvent is distilled off to give crude crystals. Washing the product with water and recrystallization from dichloromethane-ether (1:1) give colorless needles of 6-(18-hydroxy-1-oxooctadecyl)-2,3-dimethoxy-5-methylphenol (6.4 g). m.p. 101° C.
• 6-(18-Hydroxyoctadecyl)-2,3-dimethoxy-5-methylphenol (0.5 g), prepared by deacetylating the above 18-acetoxy compound in the same manner as in Reference Example 3, is dissolved in dimethylformamide (1 l) followed by addition of potassium nitrosodisulfonate (13 g), water (700 ml), methanol (100 ml) and potassium-dihydrogen phosfate (1 g). The mixture is stirred at room temperature for 45 days.
• the product is extracted in a conventional manner and recrystallized from hexane to give colorless needles of 6-(20-acetoxyeicosyl)-2,3-dimethoxy-5-methylhydroquinone-1,4-diacetate (0.31 g). m.p. 67° C.
• the effect of activating the respiration of bovine heart mitochondria deactivated by treatment with acetone was evaluated by the method of Lester and Fleischer (Biochim. Biophys. Acta, vol. 113, p. 519, 1966).
• the respiration activating effect was expressed in terms of oxygen consumption due to succinate oxidase activity, succinic acid being the substrate.
• Spontaneously hypertensive rats showing a strong tendency to cerebral apoplexy (hereinafter abbreviated to SHRSP) (Okamoto et al., Circulation Res., vol. 34-35, pp. 1-143, 1974), were newly established in 1974.
• SHRSP cerebral apoplexy
• Oral administration of the compound of the invention (15 mg/kg) consecutively for 3 weeks significantly retarded the manifestation of the apoplectic symptoms, as seen in Table 2.
• the time to the manifestation of the symptoms and the time to death were prolonged also by the administration of 100 mg/kg for 3 days or 35 mg/kg for 14 days.
• the SHRSP fed with high sodium chloride level, are liable to develop cerebral apoplexy (cerebral hemorrhage or hemorrhagic infarction) with high incidence.
• cerebral apoplexy was significantly (P ⁇ 0.05 by Wilcoxon's two sample test) inhibited in the group given the compound of the invention.
• SHRSP's were fed under sodium chloride loading as in Example 3.
• the dosed group was compared with the control group in respect of the severity of the symptoms. The severity was scored (0 for no symptoms to 5 for the severest) for each individual and the results were expressed in terms of the total score for the respective group.
• the administration of the compound of the present invention alleviated the clinical symptoms after manifestation of the apoplexy. The body weight loss after the apoplexy was also depressed.
• the compound of the invention also suppressed a development of malignant hypertension, judging from proteinuria and body weight loss which are indexes of aggravation of hypertension.
• the kidney of each normal rat was unilaterally excised, and desoxycorticosterone acetate (10 mg/kg) was administered subcutaneously once a week.
• the rats were given a 1% aqueous sodium chloride solution as drinking water.
• Table 6 the compound of the present invention inhibited the aggravation development of malignant hypertension.
• the compounds of the present invention exhibit a protecting effect against heart failure.
• Table 7 the widening of the QRS wave interval, an index of heart failure, was prevented.
• the tissue lactic acid level, an index of myocardinal energy state was lowered.
• the above ingredients are mixed in a conventional manner and gelatin capsules are filled with the mixture to prepare capsules.
• the above ingredients are mixed and made into tablets in a conventional manner.
• Nikkol HCO-120® Polyoxyethylene hydrogenated ricinolate; Produced by Nikko Chemicals
• To the solution are added 0.4 g of monosodium phosphate and 0.1 g of disodium phosphate to make the pH about 6.
• the mixture is filled in containers, followed by sealing and heat sterilization to prepare an injectable solution.
• the above ingredients are mixed to make a solution and then soft capsules are filled with the solution in a conventional manner.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Biomedical Technology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Indole Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=15917438

Family Applications (1)

Country Status (9)

Cited By (21)

Families Citing this family (9)

Citations (1)

Family Cites Families (2)

• 1979
  • 1979-12-30 JP JP17112579A patent/JPS5697223A/ja active Granted
• 1980
  • 1980-12-17 US US06/217,538 patent/US4436753A/en not_active Expired - Lifetime
  • 1980-12-24 IT IT50468/80A patent/IT1144075B/it active
  • 1980-12-24 DE DE19803049039 patent/DE3049039A1/de not_active Withdrawn
  • 1980-12-29 DE DE8080304729T patent/DE3071684D1/de not_active Expired
  • 1980-12-29 AT AT80304729T patent/ATE21031T1/de not_active IP Right Cessation
  • 1980-12-29 EP EP80304729A patent/EP0031727B1/de not_active Expired
• 1987
  • 1987-12-30 MY MY652/87A patent/MY8700652A/xx unknown
• 1988
  • 1988-11-30 SG SG846/88A patent/SG84688G/en unknown
• 1989
  • 1989-08-10 HK HK640/89A patent/HK64089A/xx not_active IP Right Cessation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events